Second-generation antipsychotics in children: Risks and monitoring needs.
Lambert C, Panagiotopoulos C, Davidson J, Goldman RD. Second-generation antipsychotics in children: Risks and monitoring needs. Canadian Family Physician 2018, 64: 660-662. PMID: 30209096, PMCID: PMC6135131.Peer-Reviewed Original ResearchConceptsSide effectsSecond-generation antipsychotic treatmentSafety of antipsychoticsMetabolic side effectsSecond-generation antipsychoticsUse of SGAsEfficacy of treatmentPotential side effectsQuality of lifeAdjunctive metforminPediatric patientsMale patientsAntipsychotic treatmentFamily physiciansPhysical activityPatient's motherTherapeutic effortsHealthy eatingPatientsWeight gainSGAFamily practiceChildren guidelinesCanadian AlliancePotential roleAnhedonia in depression and schizophrenia: A transdiagnostic challenge
Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH. Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neuroscience & Therapeutics 2018, 24: 615-623. PMID: 29687627, PMCID: PMC6489811, DOI: 10.1111/cns.12854.Peer-Reviewed Original Research